DOCSLIB.ORG

O O2 Enzymes Available from Sigma Enzymes Available from Sigma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
O O2 Enzymes Available from Sigma Enzymes Available from Sigma COO 2.7.1.15 Ribokinase OXIDOREDUCTASES CONH2 COO 2.7.1.16 Ribulokinase 1.1.1.1 Alcohol dehydrogenase BLOOD GROUP + O O + O O 1.1.1.3 Homoserine dehydrogenase HYALURONIC ACID DERMATAN ALGINATES O-ANTIGENS STARCH GLYCOGEN CH COO N COO 2.7.1.17 Xylulokinase P GLYCOPROTEINS SUBSTANCES 2 OH N + COO 1.1.1.8 Glycerol-3-phosphate dehydrogenase Ribose -O - P - O - P - O- Adenosine(P) Ribose - O - P - O - P - O -Adenosine NICOTINATE 2.7.1.19 Phosphoribulokinase GANGLIOSIDES PEPTIDO- CH OH CH OH N 1 + COO 1.1.1.9 D-Xylulose reductase 2 2 NH .2.1 2.7.1.24 Dephospho-CoA kinase O CHITIN CHONDROITIN PECTIN INULIN CELLULOSE O O NH O O O O Ribose- P 2.4 N N RP 1.1.1.10 l-Xylulose reductase MUCINS GLYCAN 6.3.5.1 2.7.7.18 2.7.1.25 Adenylylsulfate kinase CH2OH HO Indoleacetate Indoxyl + 1.1.1.14 l-Iditol dehydrogenase L O O O Desamino-NAD Nicotinate- Quinolinate- A 2.7.1.28 Triokinase O O 1.1.1.132 HO (Auxin) NAD(P) 6.3.1.5 2.4.2.19 1.1.1.19 Glucuronate reductase CHOH - 2.4.1.68 CH3 OH OH OH nucleotide 2.7.1.30 Glycerol kinase Y - COO nucleotide 2.7.1.31 Glycerate kinase 1.1.1.21 Aldehyde reductase AcNH CHOH COO 6.3.2.7-10 2.4.1.69 O 1.2.3.7 2.4.2.19 R OPPT OH OH + 1.1.1.22 UDPglucose dehydrogenase 2.4.99.7 HO O OPPU HO 2.7.1.32 Choline kinase S CH2OH 6.3.2.13 OH OPPU CH HO CH2CH(NH3)COO HO CH CH NH HO CH2CH2NHCOCH3 CH O CH CH NHCOCH COO 1.1.1.23 Histidinol dehydrogenase OPC 2.4.1.17 3 2.4.1.29 CH CHO 2 2 2 3 2 2 3 O 2.7.1.33 Pantothenate kinase CH3CH NHAC OH OH OH LACTOSE 2 COO 1.1.1.25 Shikimate dehydrogenase A HO HO OPPG CH OH 2.7.1.34 Pantetheine kinase UDP- TDP-Rhamnose 2 NH NH NH NH N M 2.7.1.36 Mevalonate kinase 1.1.1.27 Lactate dehydrogenase HO COO- GDP- 2.4.1.21 O NH NH 4.1.1.28 2.3.1.5 2.1.1.4 1.1.1.29 Glycerate dehydrogenase C UDP-N-Ac-Muramate Iduronate OH 2.4.1.1 2.4.1.11 HO 5-Hydroxy- 5-Hydroxytryptamine N-Acetyl-serotonin N-Acetyl-5-O-methyl-serotonin Quinolinate 2.7.1.39 Homoserine kinase Mannuronate CH3 etc. 3.2.1.23 Indole- Indole A 1.1.1.30 3-Hydroxybutyrate dehydrogenase GDP-Fucose O 2.4.1.21 tryptophan (SEROTONIN) (MELATONIN) 2.7.1.40 Pyruvate kinase 1.1.1.31 3-Hydroxyisobutyrate dehydrogenase C CMP-N-Acetyl OH OH 2.7.1.38 acetaldehyde 1.14.16.4 T 2.7 1.47 D-Ribulokinase 1.1.1.32 Mevaldate reductase CH2OH 5.1.3.13 O 2.7.1.53 l-Xylulokinase H neuraminate CH2OH O OH + 1.1.1.34 Hydroxymethylglutaryl-CoA reductase (NADPH) HO O 5.1.3.12 OH OPPT 4.1.1.43 + COO I 2.7.1.60 N-Acylmannosamine kinase O COO 4.2.1.47 + COCH2CH(NH3)COO COO 2.4.1.33 CO CH2CH(NH3)COO CO CH CH(NH )COO 2.7.1.71 Shikimate kinase 1.1.1.35 3-Hydroxyacyl-CoA dehydrogenase A CHOH 2.4.1.16 OH CH OH GALACTOSE 2 3 CHOH COO - ADP- 2 CH2COCOO CHO NH2 NH2 OCH OCH NH C 2.7.1.80 Pyrophosphate—serine phosphotransferase 1.1.1.37 Malate dehydrogenase AcNH COO HO OH HO OPPG CH OH O NH NH2 2 OH OPPU O 2 TDP-4-Oxo- NH 2 OH OH COO COO 2.7.1.82 Ethanolamine kinase 1.1.1.39 Malate dehydrogenase (decarboxylating) R CH2OH O OH CH OH 4.1.99.1 HO Glucose 2 NH 3.5.1.9 1.14.13.9 3.7.1.3 1.13.11.6 4.1.1.45 1.1.1.41 Isocitrate dehydrogenase (NAD+) OH 2.7.7.43 CH OH 6-deoxyglucose 2.7.1.6 O Formylkynurenine Kynurenine 3-Hydroxy 3-Hydroxy 2-Amino-3-carboxy 2-Aminomuconate- 2.7.1.107 Diacylglycerol kinase 1.1.1.158 2 NHCOCH3 GDP-Mannose HO 1.1.1.44 Phosphogluconate dehydrogenase I 3.1.3.29 O HO OH OPPU Indolepyruvate A 2.7.2.3 Phosphoglycerate kinase OH OPPU kynurenine anthranilate muconate semialdehyde 6-semialdehyde 2.7.2.4 Aspartate kinase (decarboxylating) HO UDP-N-Ac- HO OH HO OH D CH2OH HO 1 1.13.11.11 COO 2.7.2.6 Formate kinase 1.1.1.45 l-Gulonate dehydrogenase OH GDP-Glucose OH O P 2.4.1.22 . H H Catechol M N-Ac-Neuraminate O 4 COO 1.1.1.49 Glucose-6-phosphate dehydrogenase HO O OPPU Galactosamine MANNOSE UDP-Glucose .1 + 2.7.2.11 Glutamate 5-kinase E (Sialate) UDP- 2.7.7.13 4.2.1.46 OH .1 CH2CH(NH3)COO NH C C CH CH OP 1.2.1.32 1.1.1.56 Ribitol dehydrogenase CH C COO CH CH NH 9 C-CH(OH)CH(OH)CH 2OP HOC-CH(OH)CH(OH)CH OP 2 I 2.7.3.2 Creatine kinase CH OP 2 NHAC 1.1.22 Galactose-P 2 2 2 2 COO 1.1.1.79 Glyoxylate reductase (NADP+) 2 Galacturonate 2.7.1.7 1. 2.7.7.27 CH CH OH OH 1.14.12.1 2.7.4.2 Phosphomevalonate kinase S COO O OP NH N NH 1.1.1.81 Hydroxypyruvate reductase O HO OH HO CH2OH NH 4.2.1.20 N O 2 N 2.7.4.3 Adenylate kinase 4.1.1.28 H H 4.1.1.48 2.4.2.18 OOC NH2 1.1.1.82 Malate dehydrogenase (NADP+) UDP-N-Ac- Mannose-1-P O 2.7.4.4 Nucleoside-phosphate kinase 3.1.3.29 5.1.3.7 2.7.7.34 2.7.7.9 HO Tryptamine Indole-3-glycerol-P 1-(o-Carboxy phenylamino) N-(5-P-Ribosyl) Anthranilate OOC O 1.1.1.85 3-Isopropylmalate dehydrogenase ACNH CH OP TDP-Glucose 5.1.3.2 2.7.4.6 Nucleoside-diphosphate kinase 4.1.3.20 Glucosamine HO OH OPPU 5.1.3.6 2 COO TRYPTOPHAN 2-Amino HO OH OH O 2.7.7.10 1-deoxyribulose-5-P anthranilate 2.7.4.8 Guanylate kinase 1.1.1.86 Ketol-acid reductoisomerase 2.7.7.12 OC pyruvate OH OH OPPU HO COO muconate 2.7.4.9 dtmp kinase 1.1.1.95 Phosphoglycerate dehydrogenase CH OH COO COO COO COO OOC CH COCOO UDP-Glucuronate 5.4.2.8 2.7.7.24 2 POCH2 CH2 COO 2 1.1.1.100 3-Oxoacyl-[acyl-carrier-protein] reductase N-Ac-Mannosamine-6-P O OH 4.1.3.27 A 2.7.4.14 Cytidylate kinase CH OH CH OH HO OHHO OH 1.1.1.102 3-Dehydrosphinganine reductase CH OH 2 2 CH2OP HOCH HCOH CH2 CH 2.7.6.1 Ribose-phosphate pyrophosphokinase 2 O 4.1.3.20 2 1.1.1.105 Retinol dehydrogenase O O O OH OH C 2.7.7.3 Pantetheine-phosphate adenylyltransferase C HO OH P OH O-C-COO HO O P O O O P O OC-COO 2.7.7.4 Sulfate adenylyl transferase 1.1.1.130 3-Dehydro-L-gulonate 2-dehydrogenase 2.7.1.60 Mannose-6-P 2.4.1.13 CH OP OH UDP-Galactose H OH OH OH OH OH OH OH OH I 1.1.1.157 3-Hydroxybutyryl-CoA dehydrogenase H ACNH 2 4.6.1.3 4.2.1.10 1.1.1.25 2.7.1.71 2.5.1.19 4.6.1.4 5.4.99.5 2.7.7.6 RNA nucleotidyltransferase (DNA-directed) HO OH OPPU OH P O HO 3-Deoxy-D-arabino- Dehydro- Dehydro- Shikimate Shikimate-3-P Shikimate-5 Chorismate Prephenate 1.1.1.158 UDP-N-acetylmuramate dehydrogenase HO OH OH HO O HO OH OH 2.4.1.9 D 2.7.7.7 DNA nucleotidyltransferase (DNA-directed) 1.1.1.169 2-Dehydropantoate 2-reductase E NHAC heptulosonate-7-P quinate shikimate enolpyruvate 3-P 2.7.7.9 UTP—glucose-1-phosphate uridylyltransferase NHCOCH3 5.4.2.3 NHCOCH O PEP + + 1.1.1.204 Xanthine dehydrogenase 3 Glucose-1-P O OH CH COCOO (NH ) CH CH( N H ) C OO 2.7.7.10 UTP—hexose-1-phosphate uridylyltransferase HO OH OH CH OH 2 CH2CH 3 C OO 2 3 CH COCOO S 1.1.1.205 IMP-dehydrogenase X N-Ac-Mannosamine UDP-N-Ac-Glucosamine N-Ac-Glucosamine-1-P N-Ac-Glucosamine-6-P 2 2 2.7.7.12 UDP glucose—hexose-1-phosphate 2 O CH2COO 4.2.1.51 1.1.3.8 l-Gulonolactone oxidase 5.1.3.14 2.7.7.23 .3.1 O uridylyltransferase O .4 NH2 O 1.1.3.22 Xanthine oxidase H H OH -OOC CH COO CH2COO 2.7.7.13 Mannose-1-phosphate guanylyltransferase COO OH OH OH OH 2 COO 1.3.1.13 1.1.99.1 Choline dehydrogenase 5.3.1.8 Glucosamine-6-P HO OH OH OH OH 2.7.7.14 Ethanolamine-phosphate cytidylyltransferase S O HOCH C C C CO CH OH OH 5.2.1.2 1.13.11.5 1.13.11.27 2.6.1.5 1.14.16.1 2.6.1.5 1.1.99.5 Glycerol-3-phosphate dehydrogenase OH 2 2 2.7.7.15 Choline-phosphate cytidylyltransferase OH H OH OH OP Fumaryl Maleyl Homogentisate Hydroxyphenyl TYROSINE PHENYLALANINE Phenylpyruvate 1.2.1.3 Aldehyde dehydrogenase (NAD+) OH OH H OH 4.3.
Load more

Recommended publications
  • KO Kidney.Xlsx
    Supplemental Table 18: Dietary Impact on the CGL KO Kidney Sulfhydrome DR/AL Accession Molecular Cysteine Spectral Protein Name Number Alternate ID Weight Residues Count Ratio P‐value Ig gamma‐2A chain C region, A allele P01863 (+1) Ighg 36 kDa 10 C 5.952 0.03767 Heterogeneous nuclear ribonucleoprotein M Q9D0E1 (+1) Hnrnpm 78 kDa 6 C 5.000 0.00595 Phospholipase D3 O35405 Pld3 54 kDa 8 C 4.167 0.04761 Ig kappa chain V‐V region L7 (Fragment) P01642 Gm10881 13 kDa 2 C 2.857 0.01232 UPF0160 protein MYG1, mitochondrial Q9JK81 Myg1 43 kDa 7 C 2.333 0.01613 Copper homeostasis protein cutC homolog Q9D8X1 Cutc 29 kDa 7 C 10.333 0.16419 Corticosteroid‐binding globulin Q06770 Serpina6 45 kDa 3 C 10.333 0.16419 28S ribosomal protein S22, mitochondrial Q9CXW2 Mrps22 41 kDa 2 C 7.333 0.3739 Isoform 3 of Agrin A2ASQ1‐3 Agrn 198 kDa 2 C 7.333 0.3739 3‐oxoacyl‐[acyl‐carrier‐protein] synthase, mitochondrial Q9D404 Oxsm 49 kDa 11 C 7.333 0.3739 Cordon‐bleu protein‐like 1 Q3UMF0 (+3)Cobll1 137 kDa 10 C 5.833 0.10658 ADP‐sugar pyrophosphatase Q9JKX6 Nudt5 24 kDa 5 C 4.167 0.15819 Complement C4‐B P01029 C4b 193 kDa 29 C 3.381 0.23959 Protein‐glutamine gamma‐glutamyltransferase 2 P21981 Tgm2 77 kDa 20 C 3.381 0.23959 Isochorismatase domain‐containing protein 1 Q91V64 Isoc1 32 kDa 5 C 3.333 0.10588 Serpin B8 O08800 Serpinb8 42 kDa 11 C 2.903 0.06902 Heterogeneous nuclear ribonucleoprotein A0 Q9CX86 Hnrnpa0 31 kDa 3 C 2.667 0.5461 Proteasome subunit beta type‐8 P28063 Psmb8 30 kDa 5 C 2.583 0.36848 Ig kappa chain V‐V region MOPC 149 P01636 12 kDa 2 C 2.583 0.36848
    [Show full text]
  • Causes and Evaluation of Mildly Elevated Liver Transaminase Levels ROBERT C
    Causes and Evaluation of Mildly Elevated Liver Transaminase Levels ROBERT C. OH, LTC, MC, USA, and THOMAS R. HUSTEAD, LTC, MC, USA Tripler Army Medical Center Family Medicine Residency Program, Honolulu, Hawaii Mild elevations in levels of the liver enzymes alanine transaminase and aspartate transaminase are commonly dis- covered in asymptomatic patients in primary care. Evidence to guide the diagnostic workup is limited. If the history and physical examination do not suggest a cause, a stepwise evaluation should be initiated based on the prevalence of diseases that cause mild elevations in transaminase levels. The most common cause is nonalcoholic fatty liver disease, which can affect up to 30 percent of the population. Other common causes include alcoholic liver disease, medication- associated liver injury, viral hepatitis (hepatitis B and C), and hemochromatosis. Less common causes include α1-antitrypsin deficiency, autoimmune hepatitis, and Wilson disease. Extrahepatic conditions (e.g., thyroid disorders, celiac disease, hemolysis, muscle disorders) can also cause elevated liver transaminase levels. Initial testing should include a fasting lipid profile; measurement of glucose, serum iron, and ferritin; total iron-binding capacity; and hepa- titis B surface antigen and hepatitis C virus antibody testing. If test results are normal, a trial of lifestyle modification with observation or further testing for less common causes is appropriate. Additional testing may include ultrasonog- raphy; measurement of α1-antitrypsin and ceruloplasmin; serum protein electrophoresis; and antinuclear antibody, smooth muscle antibody, and liver/kidney microsomal antibody type 1 testing. Referral for further evaluation and possible liver biopsy is recommended if transaminase levels remain elevated for six months or more.
    [Show full text]
  • United States Patent 19 11 Patent Number: 5,780,253 Subramanian Et Al
    III USOO5780253A United States Patent 19 11 Patent Number: 5,780,253 Subramanian et al. (45) Date of Patent: Jul. 14, 1998 54 SCREENING METHOD FOR DETECTION OF 4.433.999 2/1984 Hyzak ....................................... 71.03 HERBCDES 4.6–552 2/1987 Anoti et al. if O3. 4,802,912 2/1989 Baker ........................................ 7/103 Inventors: Wenkiteswaran Subramanian Danville: Anne G. Toschi. Burlingame. OTHERTHER PPUBLICATION CATIONS both of Calif. Heim et al. Pesticide Biochem & Physiol; vol. 53, pp. 138-145 (1995). 73) Assignee: Sandoz Ltd., Basel. Switzerland Hatch. MD.: Phytochem. vol. 6... pp. 115 to 119, (1967). Haworth et al. J. Agric. Food Chem, vol. 38, pp. 1271-1273. 21 Appl. No.:752.990 1990. Nishimura et al: Phytochem: vol. 34, pp. 613-615. (1993). 22 Filed: Nov. 21, 1996 Primary Examiner-Louise N. Leary Related U.S. Application Data Attorney, Agent, or Firm-Lynn Marcus-Wyner: Michael P. Morris 63 Continuation of Ser. No. 434.826, May 4, 1995, abandoned. 6 57 ABSTRACT 51 Int. Cl. ............................... C12Q 1/48: C12Q 1/32: C12Q 1/37; C12O 1/00 This invention relates to novel screening methods for iden 52 U.S. Cl. ................................. 435/15:435/18: 435/26: tifying compounds that specifically inhibit a biosynthetic 435/23: 435/4, 536/23.6:536/23.2:536/24.3 pathway in plants. Enzymes which are specifically affected 536/26.11:536/26.12:536/26.13 by the novel screening method include plant purine biosyn 58 Field of Search .................................. 435/15, 8, 26, thetic pathway enzymes and particularly the enzymes 435/23 4: 536/23.6, 23.2, 24.3, 26.1, involved in the conversion of inosine monophosphate to 26.12, 26.13 adenosine monophosphate and inosine monophosphate to guanosine monophosphate.
    [Show full text]
  • Comparison of Strand-Specific Transcriptomes Of
    Landstorfer et al. BMC Genomics 2014, 15:353 http://www.biomedcentral.com/1471-2164/15/353 RESEARCH ARTICLE Open Access Comparison of strand-specific transcriptomes of enterohemorrhagic Escherichia coli O157:H7 EDL933 (EHEC) under eleven different environmental conditions including radish sprouts and cattle feces Richard Landstorfer1, Svenja Simon2, Steffen Schober3, Daniel Keim2, Siegfried Scherer1 and Klaus Neuhaus1* Abstract Background: Multiple infection sources for enterohemorrhagic Escherichia coli O157:H7 (EHEC) are known, including animal products, fruit and vegetables. The ecology of this pathogen outside its human host is largely unknown and one third of its annotated genes are still hypothetical. To identify genetic determinants expressed under a variety of environmental factors, we applied strand-specific RNA-sequencing, comparing the SOLiD and Illumina systems. Results: Transcriptomes of EHEC were sequenced under 11 different biotic and abiotic conditions: LB medium at pH4, pH7, pH9, or at 15°C; LB with nitrite or trimethoprim-sulfamethoxazole; LB-agar surface, M9 minimal medium, spinach leaf juice, surface of living radish sprouts, and cattle feces. Of 5379 annotated genes in strain EDL933 (genome and plasmid), a surprising minority of only 144 had null sequencing reads under all conditions. We therefore developed a statistical method to distinguish weakly transcribed genes from background transcription. We find that 96% of all genes and 91.5% of the hypothetical genes exhibit a significant transcriptional signal under at least one condition. Comparing SOLiD and Illumina systems, we find a high correlation between both approaches for fold-changes of the induced or repressed genes. The pathogenicity island LEE showed highest transcriptional activity in LB medium, minimal medium, and after treatment with antibiotics.
    [Show full text]
  • Dysregulated Hepatic Methionine
    Virginia Commonwealth University VCU Scholars Compass Internal Medicine Publications Dept. of Internal Medicine 2015 Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease Tommy Pacana Virginia Commonwealth University, [email protected] Sophie Cazanave Virginia Commonwealth University Aurora Verdianelli Virginia Commonwealth University See next page for additional authors Follow this and additional works at: http://scholarscompass.vcu.edu/intmed_pubs Part of the Medicine and Health Sciences Commons Copyright: © 2015 Pacana et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Downloaded from http://scholarscompass.vcu.edu/intmed_pubs/98 This Article is brought to you for free and open access by the Dept. of Internal Medicine at VCU Scholars Compass. It has been accepted for inclusion in Internal Medicine Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Authors Tommy Pacana, Sophie Cazanave, Aurora Verdianelli, Viashali Patel, Hae-Ki Min, Faridoddin Mirshahi, Eoin Quinlavin, and Arun J. Sanyal This article is available at VCU Scholars Compass: http://scholarscompass.vcu.edu/intmed_pubs/98 RESEARCH ARTICLE Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty
    [Show full text]
  • Part One Amino Acids As Building Blocks
    Part One Amino Acids as Building Blocks Amino Acids, Peptides and Proteins in Organic Chemistry. Vol.3 – Building Blocks, Catalysis and Coupling Chemistry. Edited by Andrew B. Hughes Copyright Ó 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32102-5 j3 1 Amino Acid Biosynthesis Emily J. Parker and Andrew J. Pratt 1.1 Introduction The ribosomal synthesis of proteins utilizes a family of 20 a-amino acids that are universally coded by the translation machinery; in addition, two further a-amino acids, selenocysteine and pyrrolysine, are now believed to be incorporated into proteins via ribosomal synthesis in some organisms. More than 300 other amino acid residues have been identified in proteins, but most are of restricted distribution and produced via post-translational modification of the ubiquitous protein amino acids [1]. The ribosomally encoded a-amino acids described here ultimately derive from a-keto acids by a process corresponding to reductive amination. The most important biosynthetic distinction relates to whether appropriate carbon skeletons are pre-existing in basic metabolism or whether they have to be synthesized de novo and this division underpins the structure of this chapter. There are a small number of a-keto acids ubiquitously found in core metabolism, notably pyruvate (and a related 3-phosphoglycerate derivative from glycolysis), together with two components of the tricarboxylic acid cycle (TCA), oxaloacetate and a-ketoglutarate (a-KG). These building blocks ultimately provide the carbon skeletons for unbranched a-amino acids of three, four, and five carbons, respectively. a-Amino acids with shorter (glycine) or longer (lysine and pyrrolysine) straight chains are made by alternative pathways depending on the available raw materials.
    [Show full text]
  • Neuroleptic Malignant Syndrome: Another Medical Cause of Acute Abdomen T.C.N
    Postgraduate Medical Journal (1989) 65, 653 - 655 Postgrad Med J: first published as 10.1136/pgmj.65.767.653 on 1 September 1989. Downloaded from Missed Diagnosis Neuroleptic malignant syndrome: another medical cause of acute abdomen T.C.N. Lo, M.R. Unwin and I.W. Dymock Department ofMedicine, Stepping Hill Hospital, Stockport, UK. Summary: We present a patient with neuroleptic malignant syndrome and intestinal pseudo- obstruction misdiagnosed as being secondary to septicaemia. The management of the patient is discussed with emphasis on the role of creatine kinase and liver function tests. Introduction Neuroleptic malignant syndrome (NMS) is an occas- (92% neutrophils), serum sodium 130 mmol/l, potas- ional but potentially lethal idiosyncratic complication sium 5.1 mmol/l, urea 8.8 mmol/l, creatinine 79 1tmol/ ofneuroleptic drugs.'"2 By February 1989 the Commit- 1, bilirubin 15 Amol/l, alanine transaminase 837 IU/i tee on Safety of Medicines had received reports of 99 (normal 7-45), aspartate transaminase 392 IU/l (nor- cases. (Committee on Safety of Medicines, personal mal 9-41), gamma glutamyl transferase 15 IU/I (nor- Protected by copyright. Communication). It is thought that the condition is mal <65), alkaline phosphatase 62 IU/I (normal underdiagnosed.34 We report on a case of NMS of 35-125). Serial electrocardiograms showed sinus which the presenting features and therapeutic comp- tachycardia with no acute change. Abdominal X-ray lications occurring during the course of the illness revealed marked gaseous distension ofsmall and large served to further our knowledge in this condition. bowels with multiple fluid levels seen on decubitus films.
    [Show full text]
  • 35 Disorders of Purine and Pyrimidine Metabolism
    35 Disorders of Purine and Pyrimidine Metabolism Georges van den Berghe, M.- Françoise Vincent, Sandrine Marie 35.1 Inborn Errors of Purine Metabolism – 435 35.1.1 Phosphoribosyl Pyrophosphate Synthetase Superactivity – 435 35.1.2 Adenylosuccinase Deficiency – 436 35.1.3 AICA-Ribosiduria – 437 35.1.4 Muscle AMP Deaminase Deficiency – 437 35.1.5 Adenosine Deaminase Deficiency – 438 35.1.6 Adenosine Deaminase Superactivity – 439 35.1.7 Purine Nucleoside Phosphorylase Deficiency – 440 35.1.8 Xanthine Oxidase Deficiency – 440 35.1.9 Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency – 441 35.1.10 Adenine Phosphoribosyltransferase Deficiency – 442 35.1.11 Deoxyguanosine Kinase Deficiency – 442 35.2 Inborn Errors of Pyrimidine Metabolism – 445 35.2.1 UMP Synthase Deficiency (Hereditary Orotic Aciduria) – 445 35.2.2 Dihydropyrimidine Dehydrogenase Deficiency – 445 35.2.3 Dihydropyrimidinase Deficiency – 446 35.2.4 Ureidopropionase Deficiency – 446 35.2.5 Pyrimidine 5’-Nucleotidase Deficiency – 446 35.2.6 Cytosolic 5’-Nucleotidase Superactivity – 447 35.2.7 Thymidine Phosphorylase Deficiency – 447 35.2.8 Thymidine Kinase Deficiency – 447 References – 447 434 Chapter 35 · Disorders of Purine and Pyrimidine Metabolism Purine Metabolism Purine nucleotides are essential cellular constituents 4 The catabolic pathway starts from GMP, IMP and which intervene in energy transfer, metabolic regula- AMP, and produces uric acid, a poorly soluble tion, and synthesis of DNA and RNA. Purine metabo- compound, which tends to crystallize once its lism can be divided into three pathways: plasma concentration surpasses 6.5–7 mg/dl (0.38– 4 The biosynthetic pathway, often termed de novo, 0.47 mmol/l). starts with the formation of phosphoribosyl pyro- 4 The salvage pathway utilizes the purine bases, gua- phosphate (PRPP) and leads to the synthesis of nine, hypoxanthine and adenine, which are pro- inosine monophosphate (IMP).
    [Show full text]
  • Metabolism of Purines and Pyrimidines in Health and Disease
    39th Meeting of the Polish Biochemical Society Gdañsk 16–20 September 2003 SESSION 6 Metabolism of purines and pyrimidines in health and disease Organized by A. C. Sk³adanowski, A. Guranowski 182 Session 6. Metabolism of purines and pyrimidines in health and disease 2003 323 Lecture The role of DNA methylation in cytotoxicity mechanism of adenosine analogues in treatment of leukemia Krystyna Fabianowska-Majewska Zak³ad Chemii Medycznej IFiB, Uniwersytet Medyczny, ul. Mazowiecka 6/8, 92 215 £ódŸ Changes in DNA methylation have been recognized tory effects of cladribine and fludarabine on DNA as one of the most common molecular alterations in hu- methylation, after 48 hr growth of K562 cells with the man neoplastic diseases and hypermethylation of drugs, are non-random and affect mainly CpG rich is- gene-promoter regions is one of the most frequent lands or CCGG sequences but do not affect sepa- mechanisms of the loss of gene functions. For this rea- rately-located CpG sequences. The analysis showed son, DNA methylation may be a tool for detection of that cladribine (0.1 mM) reduced the methylated early cell transformations as well as predisposition to cytosines in CpG islands and CCGG sequences to a sim- metastasis process. Moreover, DNA methylation seems ilar degree. The inhibition of cytosine methylation by to be a promissing target for new preventive and thera- fludarabine (3 mM) was observed mainly in CCGG se- peutic strategies. quences, sensitive to HpaII, but the decline in the meth- Our studies on DNA methylation and cytotoxicity ylated cytosine, located in CpG island was 2-fold lower mechanism of antileukemic drugs, cladribine and than that with cladribine.
    [Show full text]
  • Differentiation of Recombinant Myoblasts In
    DIFFERENTIATION OF RECOMBINANT MYOBLASTS IN ALGINATE MICROCAPSULES By KELLY MACMILLAN BOWIE, B.Sc. A Thesis Submitted to the school of Graduate Studies in Partial Fulfillment ofthe Requirements for the Degree Master ofScience McMaster University 1997 © Copyright by Kelly MacMillan Bowie, June, 1997 MASTER OF SCIENCE MCMASTER UNIVERSITY 1997 Hamilton, Ontario TITLE: Differentiation of Recombinant Myoblasts in Alginate Microcapsules AUTHOR: Kelly MacMillan Bowie, B.Sc. (University of Western Ontario) SUPERVISOR: Dr. P.L. Chang EXAMINING COMMITTEE: Dr. M.A. Rudnicki Dr. C. Nurse NUMBER OF PAGES: xii,l75 11 ABSTRACT A cost effective approach to the delivery of therapeutic gene products in vivo is to immunoprotect genetically-engineered, universal, non-autologous cells in biocompatible microcapsules before implantation. Myoblasts may be an ideal cell type for encapsulation due to their inherent ability to differentiate into myotubes, thereby eliminating the problem of cell overgrowth within the capsular space. To evaluate the interaction between the differentiation program and the secretory activity of the myoblasts within the microcapsule environment, we transfected C2C 12 myoblasts to express human growth hormone and followed their expression of muscle differentiation markers, such as creatine phosphate kinase (CPK) protein and up-regulation of muscle-specific genes (ie. myosin light chains 2 & 1/3, Troponin I slow, Troponin T, myogenin and MyoD1). As the transfected myoblasts were induced to differentiate for up to two weeks, their myogenic index (i.e. the percentage of multinucleate myoblasts) increased from 0 to -50%. Concomitantly, up-regulation of differentiation marker RNA levels, and as much as a 23-fold increase in CPK activity, were observed.
    [Show full text]
  • Discovery of an Alternate Metabolic Pathway for Urea Synthesis in Adult Aedes Aegypti Mosquitoes
    Discovery of an alternate metabolic pathway for urea synthesis in adult Aedes aegypti mosquitoes Patricia Y. Scaraffia*†‡, Guanhong Tan§, Jun Isoe*†, Vicki H. Wysocki*§, Michael A. Wells*†, and Roger L. Miesfeld*† Departments of §Chemistry and *Biochemistry and Molecular Biophysics and †Center for Insect Science, University of Arizona, Tucson, AZ 85721-0088 Edited by Anthony A. James, University of California, Irvine, CA, and approved December 4, 2007 (received for review August 27, 2007) We demonstrate the presence of an alternate metabolic pathway We previously reported that mosquitoes dispose of toxic for urea synthesis in Aedes aegypti mosquitoes that converts uric ammonia through glutamine (Gln) and proline (Pro) synthesis, acid to urea via an amphibian-like uricolytic pathway. For these along with excretion of ammonia, uric acid, and urea (20). By studies, female mosquitoes were fed a sucrose solution containing using labeled isotopes and mass spectrometry techniques (21), 15 15 15 15 15 NH4Cl, [5- N]-glutamine, [ N]-proline, allantoin, or allantoic we have recently determined how the N from NH4Cl is acid. At 24 h after feeding, the feces were collected and analyzed incorporated into the amide side chain of Gln, and then into Pro, in a mass spectrometer. Specific enzyme inhibitors confirmed that in Ae. aegypti (22). In the present article we demonstrate that the 15 15 15 mosquitoes incorporate N from NH4Cl into [5- N]-glutamine nitrogen of the amide group of Gln contributes to uric acid and use the 15N of the amide group of glutamine to produce synthesis in mosquitoes and, surprisingly, that uric acid can be 15 labeled uric acid.
    [Show full text]
  • Yeast Genome Gazetteer P35-65
    gazetteer Metabolism 35 tRNA modification mitochondrial transport amino-acid metabolism other tRNA-transcription activities vesicular transport (Golgi network, etc.) nitrogen and sulphur metabolism mRNA synthesis peroxisomal transport nucleotide metabolism mRNA processing (splicing) vacuolar transport phosphate metabolism mRNA processing (5’-end, 3’-end processing extracellular transport carbohydrate metabolism and mRNA degradation) cellular import lipid, fatty-acid and sterol metabolism other mRNA-transcription activities other intracellular-transport activities biosynthesis of vitamins, cofactors and RNA transport prosthetic groups other transcription activities Cellular organization and biogenesis 54 ionic homeostasis organization and biogenesis of cell wall and Protein synthesis 48 plasma membrane Energy 40 ribosomal proteins organization and biogenesis of glycolysis translation (initiation,elongation and cytoskeleton gluconeogenesis termination) organization and biogenesis of endoplasmic pentose-phosphate pathway translational control reticulum and Golgi tricarboxylic-acid pathway tRNA synthetases organization and biogenesis of chromosome respiration other protein-synthesis activities structure fermentation mitochondrial organization and biogenesis metabolism of energy reserves (glycogen Protein destination 49 peroxisomal organization and biogenesis and trehalose) protein folding and stabilization endosomal organization and biogenesis other energy-generation activities protein targeting, sorting and translocation vacuolar and lysosomal
    [Show full text]